Egetis Therapeutics: De-risked orphan play at a discount - Redeye

Redeye updates its view of Egetis following a change of lead analyst and an eventful year, including a de-risked strategy to market and upcoming regulatory filings. We still see significant upside in Egetis and view this as a compelling investment case as we head into an momentous 2023.

Länk till analysen i sin helhet: https://www.redeye.se/research/869315/egetis-therapeutics-de-risked-orphan-play-at-a-discount?utm_source=finwire&utm_medium=RSS